



Current Price: ₹ 4603.25

STOCK DATA

BSE Code	532488
NSE Symbol	DIVISLAB
Reuters	DIVI.BO
Bloomberg	DIVI IN

VALUE PARAMETERS

52 W H/L(Rs)	4900.00/3528.20
Mkt. Cap.(Rs Cr)	66187.67
Latest Equity(Subscribed)	71.89
Latest Reserve (cons.)	5913.18
Latest EPS (cons.) -Unit Curr.	53.18
Latest P/E Ratio -cons	86.56
Latest Bookvalue (cons.) -Unit Curr.	416.25
Latest P/BV - cons	11.06
Dividend Yield -%	0.20
Face Value	5.00

SHARE HOLDING PATTERN (%)

Description as on	% of Holding 31/03/2023
Foreign	47.77
Institutions	17.76
Govt Holding	0.23
Non Promoter Corp. Hold.	0.30
Promoters	29.33
Public & Others	4.61

Consolidated Financials Results

In Cr.

Particulars	Qtr Ending	Qtr Ending	Var. (%)
	Mar. 23	Mar. 22	
Total Income	4302.2	3546.43	21
OPM (%)	11.35	13.06	-171bps
OP	488.15	463.24	5
Other income	19.92	33.74	-41
PBIDT	508.07	496.98	2
Net Finance Charges	95.41	94.9	1
PBDT	412.66	402.08	3
Depreciation	159.06	166.4	-4
PBT	253.6	235.68	8
Tax expense	107.96	138.67	-22
PAT	145.64	97.01	50
Minority Interest	1.12	6.87	-84
Profit after Minority Interest and Share of profit of Associates	144.52	90.14	60
EPS (Rs)	10.05	6.27	

Apollo Hospitals Q4 Results: Sales up 21.31%, NP up 50%, Above Estimates

Consolidated net profit jumped 50.14% to Rs 145.64 crore in Q4 FY23 as compared to Rs 97 crore in Q4 FY22. Revenue from operations stood at Rs 4,302.20 crore during the quarter, up 21.31% from Rs 3,546.43 crore recorded in the same period last fiscal. Profit before tax rose 7.61% year on year to Rs 253.60 crore in the quarter ended 31 March 2023. Margins declined to 11.35% vs 13.06%.

During the quarter, the company's revenue from Healthcare Services was Rs 2,227.40 crore (up 18.53% YoY) and revenue from Digital Health & Pharmacy Distribution was Rs 1,799.17 crore (up 30.9% YoY) and the revenue from Retail Health & Diagnostics stood at Rs 308.47 crore (up 3.97% YoY).

On full year basis, the company's consolidated net profit declined 23.8% to Rs 844.57 crore despite of 13.3% rise in revenue from operations to Rs 16,612.45 crore in FY23 over FY22.

Meanwhile, the company's board recommended a final dividend of Rs 9 per share for the financial year ending 31 March 2023. The record date for the same is fixed on Saturday, 19 August 2023 and the dividend will be paid, subject to deduction of tax at source, on and from 9 September 2023.

Other Highlights

- Industry-wide traction seen in health seeking behaviour as well penetration of Health Insurance. Non-metro cities hold great growth promise for the future as health and wellness have become central to every household.
- It has achieved 10,000 robotics assisted surgeries, has also expanded and introduced robotic-assistive procedures to over 20 specialties.

- Group successfully completes 500 pediatric liver transplants. With 90% success rates, it has become a beacon of quality and hope for patients from across the world.
- Over 9 million AI CVD (AI enabled Cardiac risk score) completed - increasing our ability to predict risk of cardiac disease accurately. Focus on AI has the power to revolutionise digital healthcare.
- Apollo launches Institute of Genomics, in 6 centres in India, to provide targeted, precise and personalized diagnosis and treatment basis genomic understanding of each individual

Management Comment

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group said, "The first full post-pandemic year has seen Apollo make some remarkable strides in its journey of healing. Our unwavering commitment to deliver world-class healthcare has enabled us to scale new heights with our performance - both in terms of financial metrics and in the expansion of our healthcare service offerings. We have seen a substantial increase in patient engagement both in our hospitals and clinics, as well as on our digital health platform Apollo 24/7.

We have continued to broaden our services, ensuring that we focus not just on cure, but on preventive healthcare as well. At a time when the world is realizing the importance of prevention more than ever before, it is a matter of pride that Apollo has been at the forefront of this shift, recognizing that the best way to fight disease is to prevent it in the first place. One of our areas of focus is Artificial Intelligence (AI), which we believe holds the power to revolutionize preventive healthcare, by helping identify patterns, predict health risks, and enable early interventions. This year, we have invested thoughtfully in AI technologies, and the results have been heartening. They have allowed us to provide a personalized healthcare approach for every individual, taking into account their unique genetic disposition, lifestyle, and medical history.

Looking ahead, we remain committed to investing in the best technology to enable superior care, including robotics, which have the potential to transform surgical procedures and improve outcomes. We also continue our focus on digital health, and have immense belief in its ability to make quality healthcare more accessible. While innovation and technological advancements are important, we continue to focus on our ultimate goal of improving the quality of life of our patients. Every step we make, every technology we adopt, is aimed at ensuring the wellbeing of those who entrust us with their care. We look forward to the new financial year with a sense of purpose and optimism, confident that our strategic investments in preventive healthcare, AI, and robotics will pave the way for a healthier future for our patients, our communities, and the nation.

E-mail: researchfeedback@smcindiaonline.com



Corporate Office:
11/6B, Shanti Chamber,
Pusa Road, New Delhi - 110005
Tel: +91-11-30111000
www.smcindiaonline.com

Mumbai Office:
Lotus Corporate Park, A Wing 401/402,
4th Floor, Graham Firth Steel Compound,
Off Western Express Highway, Jay Coach Signal,
Goreagon (East) Mumbai - 400063
Tel: 91-22-67341600, Fax: 91-22-28805606

Kolkata Office:
18, Rabindra Sarani,
Poddar Court, Gate No.- 4, 5th Floor, Kolkata-700001
Tel: 91-33-39847000, Fax: 91-33-39847004

Investments in securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. The securities quoted are for illustration only and are not recommendatory. SMC is a SEBI registered Research Analyst having registration number INH100001849. CIN : L74899DL1994PLC063609.

SMC Global Securities Ltd. (hereinafter referred to as "SMC") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. SMC is a registered member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited, MSEI (Metropolitan Stock Exchange of India Ltd) and M/s SMC Comtrade Ltd is a registered member of National Commodity and Derivative Exchange Limited and Multi Commodity Exchanges of India and other commodity exchanges in India. SMC is also registered as a Depository Participant with CDSL and NSDL. SMC's other associates are registered as Merchant Bankers, Portfolio Managers, NBFC with SEBI and Reserve Bank of India. It also has registration with AMFI as a Mutual Fund Distributor.

SMC is a SEBI registered Research Analyst having registration number INH100001849. SMC or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities market. SMC or its associates or its Research Analyst or his relatives do not hold any financial interest in the subject company interest at the time of publication of this Report. SMC or its associates or its Research Analyst or his relatives do not hold any actual/beneficial ownership of more than 1% (one percent) in the subject company, at the end of the month immediately preceding the date of publication of this Report. SMC or its associates its Research Analyst or his relatives does not have any material conflict of interest at the time of publication of this Report.

SMC or its associates/analyst has not received any compensation from the subject company covered by the Research Analyst during the past twelve months. The subject company has not been a client of SMC during the past twelve months. SMC or its associates has not received any compensation or other benefits from the subject company covered by analyst or third party in connection with the present Research Report. The Research Analyst has not served as an officer, director or employee of the subject company covered by him/her and SMC has not been engaged in the market making activity for the subject company covered by the Research Analyst in this report.

The views expressed by the Research Analyst in this Report are based solely on information available publicly available/internal data/ other reliable sources believed to be true. SMC does not represent/ provide any warranty expressly or impliedly to the accuracy, contents or views expressed herein and investors are advised to independently evaluate the market conditions/risks involved before making any investment decision. The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the subject company.

Disclaimer: This Research Report is for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to the investor. It is only for private circulation and use. The Research Report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of this Research Report. The Research Report should not be reproduced or redistributed to any other person(s) in any form without prior written permission of the SMC. The contents of this material are general and are neither comprehensive nor inclusive. Neither SMC nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this Research Report. It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions. Please note that SMC its affiliates, Research Analyst, officers, directors, and employees, including persons involved in the preparation or issuance of this Research Report: (a) from time to time, may have long or short positions in, and buy or sell the securities thereof, of the subject company(ies) mentioned here in; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company(ies) discussed herein or may perform or seek to perform investment banking services for such company(ies) or act as advisor or lender/borrower to such subject company(ies); or (c) may have any other potential conflict of interest with respect to any recommendation and related information and opinions. All disputes shall be subject to the exclusive jurisdiction of Delhi High court.